Cortex

About Cortex

Cortex aims to transform the diagnosis and treatment of atrial arrhythmias by providing insight into each individual patient's disease pathophysiology. The company leverages multimodal AI in medtech to drive new technologies and impact patient outcomes.

Products & Services

OptiMap System:A 510(k) cleared, advanced mapping system that calculates Electrographic Flow (EGF) from unipolar electrogram signals using a 64-electrode basket catheter. It employs AI and optical flow algorithms to reconstruct chaotic electrical conduction in atrial fibrillation, enabling personalized treatment strategies.

Specialties

Atrial Fibrillation Mapping Electrographic Flow (EGF) Technology AI in Medical Technology Personalized Cardiac Arrhythmia Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity T: - FT: Equity	A: 90000000 MR: - FA: $90 million FAN: 90000000	D: 2023-12-07 FD: 2023-12-07	3 investors

Equity Latest

2023-12-07

$90.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Matthew Lungren

Chief Data Science Officer for Microsoft Health & Life Sciences

N

Nilsson KR

C

Castellano S

K

Kong MH

Chief Clinical Officer

D

Derejko P

S

Szili-Torok T

View 31 more team members with Pro

Unlock Full Team Directory

Recent News

Cortex Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised